3.195
0.79%
+0.025
GT Biopharma Inc stock is currently priced at $3.195, with a 24-hour trading volume of 7,792.
It has seen a +0.79% increased in the last 24 hours and a -23.93% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.22 pivot point. If it approaches the $2.99 support level, significant changes may occur.
Previous Close:
$3.17
Open:
$3.48
24h Volume:
7,792
Market Cap:
$4.41M
Revenue:
-
Net Income/Loss:
$-7.60M
P/E Ratio:
-6.9457
EPS:
-0.46
Net Cash Flow:
$-8.85M
1W Performance:
-14.84%
1M Performance:
-23.93%
6M Performance:
+1,079%
1Y Performance:
+826.09%
GT Biopharma Inc Stock (GTBP) Company Profile
Name
GT Biopharma Inc
Sector
Industry
Phone
415 919 4040
Address
8000 Marina Boulevard, Suite 100, Brisbane
GT Biopharma Inc Stock (GTBP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-24-21 | Initiated | H.C. Wainwright | Buy |
Apr-13-21 | Initiated | B. Riley Securities | Buy |
Mar-17-21 | Initiated | ROTH Capital | Buy |
GT Biopharma Inc Stock (GTBP) Latest News
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
GlobeNewswire Inc.
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
GlobeNewswire Inc.
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders
GlobeNewswire Inc.
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
GlobeNewswire Inc.
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
GlobeNewswire Inc.
GT Biopharma Inc Stock (GTBP) Financials Data
GT Biopharma Inc (GTBP) Net Income 2024
GTBP net income (TTM) was -$7.60 million for the quarter ending December 31, 2023, a +63.62% increase year-over-year.
GT Biopharma Inc (GTBP) Cash Flow 2024
GTBP recorded a free cash flow (TTM) of -$8.85 million for the quarter ending December 31, 2023, a +41.83% increase year-over-year.
GT Biopharma Inc (GTBP) Earnings per Share 2024
GTBP earnings per share (TTM) was -$5.5836 for the quarter ending December 31, 2023, a +71.75% growth year-over-year.
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Cap:
|
Volume (24h):